Novo Nordisk Bets on Pills and Partnerships as CagriSema Data Faces Regulatory Test

Novo Nordisk sees oral drugs taking half the obesity market by 2030, as CagriSema data and a CFRA downgrade shape the debate.

Novo Nordisk's leadership believes the future of obesity treatment will increasingly be swallowed, not injected. CEO Mike Doustdar told Reuters on Tuesday that oral medications could capture as much as half of the global market for obesity drugs by 2030 — a projection that underpins a widening push by the Danish drugmaker into novel delivery formats.

That strategy has translated into a string of deals. On 17 September, Novo Nordisk signed an agreement with Orbis Medicines worth up to USD 1.4 billion to research oral cardiometabolic therapies, covering upfront payments, milestones and a strategic equity stake in the partner. A separate worldwide licence secured from Sweden's Nanexa on Friday carries a total value of up to roughly EUR 1.17 billion, granting exclusive rights to the PharmaShell technology across as many as five development programmes for long-acting injections in obesity, type 2 diabetes and other cardiometabolic conditions. Under that arrangement, Nanexa stands to receive up to EUR 1.165 billion, of which EUR 615 million relates to upfront, development and regulatory milestones, while Novo Nordisk takes on global development and commercialisation.

Technology is being folded into discovery work as well. A partnership agreed on 16 September with Anthropic will see the Claude models support development workflows, analyse scientific questions and automate clinical study reporting.

Clinical Edge Meets a Demanding Market

The centrepiece of Novo Nordisk's next-generation pipeline remains CagriSema, and the phase 3 results published on 21 September have sharpened the debate. In adults with type 2 diabetes, the combination achieved 12.4% average weight loss after roughly 60 weeks of treatment, against 9.1% for rival tirzepatide. In a further trial involving overweight patients, weight reduction reached 21% compared with the control group. Novo Nordisk has said it will now align the regulatory pathway for the type 2 diabetes indication with authorities — a step that carries growing urgency, since investors are demanding hard evidence of future market leadership after a stretch of muted responses to strategic announcements.

Whether the company can defend its therapeutic lead in the lucrative metabolic disease market is now the pivotal question. The head-to-head comparison with tirzepatide serves as the key yardstick for future earnings power. An efficacy advantage of just over three percentage points gives the Danes a visible edge, though that edge still has to prove itself in regulatory practice. Should Novo Nordisk demonstrate that the clinical benefit comes without a tolerability penalty, it would cement the foundation for the era after semaglutide. If the therapeutic gap is instead seen as marginal by regulators and physicians, future premium pricing comes under pressure.

Analyst Downgrade and Pricing Pressure

Not everyone is convinced. CFRA cut its rating on Novo Nordisk's US depositary receipts from hold to sell on Tuesday, setting a price target of USD 38. Reuters reported that market participants have found the company's longer-term growth ambitions underwhelming, with Evan Seigerman of BMO noting that annual revenue growth of 3.6% is already priced in. Beyond intensifying price competition and looming patent expirations, management itself has acknowledged that its 2030 targets carry uncertainties and do not constitute binding financial guidance. Should market growth flatten earlier than expected, the operating margin would face a test.

The company's own long-range ambitions remain substantial: risk-adjusted pipeline revenue of more than DKK 150 billion by 2035, and the launch of more than five products with multi-blockbuster potential by 2030.

Patent Challenge in Delaware

Pressure on the existing product line surfaced in a federal court in Delaware on Friday, when Viatris subsidiary Mylan Pharmaceuticals filed suit against Novo Nordisk. Mylan is seeking a judicial declaration that a planned Wegovy generic does not infringe patents covering single-dose pens for weight reduction.

What Comes Next

A near-term milestone arrives quickly. From 28 September to 2 October, Novo Nordisk will present 44 pieces of research on semaglutide, CagriSema and Zenagamtid at the annual meeting of the European Association for the Study of Diabetes in Milan. The details unveiled there will provide the next test of the pipeline's durability. An FDA decision on the weight-management application is expected in the fourth quarter.

The stock closed Friday at EUR 34.05, down 23% since the start of the year and 38% below its 52-week high — a valuation that reflects how the transition to a more competitive landscape is being read on the trading floor.